menu
    • menu

    Company profile for CytoAgents

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of COVID-19, Influenza and other viral infectious diseases. Using a novel, host-directed approach, we target the underlying cause of life-threatening symptoms associated with COVID-19, Influenza and Cytokine Releasing Syndrome by modulating the natural immune response to the disease. We are co...
    CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of COVID-19, Influenza and other viral infectious diseases. Using a novel, host-directed approach, we target the underlying cause of life-threatening symptoms associated with COVID-19, Influenza and Cytokine Releasing Syndrome by modulating the natural immune response to the disease. We are committed to developing first-in-class, best-in-class products that meet a major medical need now and into the future.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CytoAgentsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Alloy 26 100 S. Commmons Suite 102 Pittsburgh, PA 15212
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://cytoagents.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/cytoagents/about/?viewAsMember=true
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cytoagents Gets 4th NIH Grant For Cytokine Release Syndrome
    Cytoagents Gets 4th NIH Grant For Cytokine Release Syndrome

    01 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-01/cytoagents-receives-fourth-grant-from-national-institutes-of-health-to-advance-research-on-cytokine

    PHARMIWEB
    01 Oct 2025
    Share Share
    CytoAgents Completes Cohort 1 Dose-escalation in Phase 1B Study
    CytoAgents Completes Cohort 1 Dose-escalation in Phase 1B Study

    24 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250424559289/en/CytoAgents-Announces-Completion-of-Cohort-1-Dose-escalation-Stage-of-Clinical-Phase-1B-to-Advance-Research-on-Cytokine-Release-Syndrome

    BUSINESSWIRE
    24 Apr 2025
    Share Share
    CytoAgents Announces Initiation of Patient Enrollment in Phase 1b/2a Trial
    CytoAgents Announces Initiation of Patient Enrollment in Phase 1b/2a Trial

    17 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231017178717/en

    BUSINESSWIRE
    17 Oct 2023
    Share Share
    CytoAgents receives FDA IND approval to begin trial of CRS therapy
    CytoAgents receives FDA IND approval to begin trial of CRS therapy

    12 May 2023

    // CLINICAL TRIALS ARENA

    https://www.clinicaltrialsarena.com/news/cytoagents-crs-trial/

    CLINICAL TRIALS ARENA
    12 May 2023
    Share Share
    CytoAgents Announces FDA Acceptance of IND Application for CTO1681
    CytoAgents Announces FDA Acceptance of IND Application for CTO1681

    11 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230511005053/en

    BUSINESSWIRE
    11 May 2023
    Share Share
    CytoAgents Announces Appointment of New Chief Medical Officer
    CytoAgents Announces Appointment of New Chief Medical Officer

    07 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220907005040/en

    BUSINESSWIRE
    07 Sep 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search